驾驭分歧视角:药物安全中的推理、证据与决策
本文分析药物安全决策中利益相关者意见分歧的来源,提出涵盖证据评估、解释与行动三个核心维度的结构化框架,强调多学科协作与清晰沟通,以提升决策透明度与一致性。
要点
- 药物安全决策需整合多元证据、科学推理与临床判断,是复杂迭代过程。
- 分歧常源于数据解读、方法学及关注或行动阈值的差异。
- 结构化框架涵盖证据评估、解释与行动,区分定量与定性考量。
核心结论
- 采用结构化框架并促进开放对话可增强药物安全决策的透明度与一致性。
研究设计与样本
- 本文为方法学论述,未报告系统检索范围或样本量。
主要发现
- 利益相关者意见分歧常源于数据解读、方法学及关注或行动阈值差异。
- 框架区分定量方面(效应大小与测量误差)与定性考量(情境解释与风险阈值)。
临床怎么用
- 安全专业人员应主动与其他科学与监管利益相关者协作,确保全面评估证据。
- 需向更广泛受众清晰沟通药物安全评估的复杂性,促进跨学科对话。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Decision making in drug safety is a complex and iterative process that requires the integration of diverse evidence sources, scientific reasoning, and clinical judgment. Diverging opinions among stakeholders-including pharmacovigilance professionals, regulatory authorities, clinical researchers, statisticians, and epidemiologists-often stem from differences in data interpretation, methodological approaches, and thresholds for concern or action. This paper examines the key sources of these divergences and presents a structured framework to enhance alignment in drug safety decision making. The proposed framework outlines three core dimensions: evidence assessment, interpretation, and action. It distinguishes between quantitative aspects, such as effect magnitude and measurement error, and qualitative considerations, including contextual interpretation and risk thresholds. The framework also underscores the importance of multidisciplinary collaboration, as safety professionals must actively engage with other scientific and regulatory stakeholders to ensure a comprehensive evaluation of the evidence. A fundamental challenge in pharmacovigilance is the need to communicate the complexities of drug safety assessment to a broader audience, including those who may not be familiar with the nuances of safety decision making. This paper aims to serve not only as a resource for new pharmacovigilance professionals, but also as a tool to facilitate clearer communication between disciplines. By adopting a structured approach and fostering open dialogue, drug safety professionals can enhance transparency and improve regulatory and clinical decision-making processes.
引用
- Hammad TA, Davies S. Navigating Diverging Perspectives: Reasoning, Evidence, and Decision-Making in Drug Safety. Drug Saf. 2025. PMID: 40075033. doi:10.1007/s40264-025-01537-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。